PDF herunterladen
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2021; 42(01): 028-034
DOI: 10.1055/s-0041-1729729
Review Article

“Radiation Recall Phenomenon” with Novel Cytotoxic Agents: An Emerging Trend in the Last Decade

Avik Mandal
1   Department of Radiation Oncology, All India Institute of Medical Sciences, Patna, Bihar, India
,
Pritanjali Singh
1   Department of Radiation Oncology, All India Institute of Medical Sciences, Patna, Bihar, India
,
Sarthak Tandon
2   Department of Radiation Oncology, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India
,
Dharmendra Singh
1   Department of Radiation Oncology, All India Institute of Medical Sciences, Patna, Bihar, India
› Institutsangaben
› Weitere Informationen
   Lizenzen und Reprints

Abstract

Radiation recall phenomenon (RRP) is an acute inflammatory reaction manifested in the previously irradiated tissues after the administration of various pharmacologic compounds. While skin manifestations are the most common clinical features, patients may also present with visceral recall events including pneumonitis, hematuria, myopathy, and mucositis if any particular organ was exposed to the prior radiation portals. This article has reviewed the published case reports, case series, abstracts, and poster presentations in the past 10 years in any language on RRP caused by various novel cytotoxic drugs including immunotherapies, molecularly targeted agents, and unconventional chemotherapies. We retrieved the data through the literature search of MEDLINE and PubMed using the keywords “radiation,” “recall,” “targeted therapy,” and “immunotherapy,” and references identified in retrieved articles were also used for further search of the literature. With the increasing use of unconventional, novel cytotoxic agents and targeted molecules, concurrent or sequentially with radiation, we expect more incidences of RRP in future that may present with either dermatological or visceral recall reactions.

Keywords

immunotherapy - radiation - recall - targeted therapy


Publikationsverlauf

Artikel online veröffentlicht:
22. Mai 2021

© 2021. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 D’Angio GJ, Farber S, Maddock CL. Potentiation of x-ray effects by actinomycin D. Radiology 1959; 73: 175-177
    CrossrefPubMedGoogle Scholar
  • 2 Kang SK. Images in clinical medicine. Radiation recall reaction after antimicrobial therapy. N Engl J Med 2006; 354 (06) 622
    CrossrefPubMedGoogle Scholar
  • 3 Wernicke AG, Swistel AJ, Parashar B, Myskowski PL. Levofloxacin-induced radiation recall dermatitis: a case report and a review of the literature. Clin Breast Cancer 2010; 10 (05) 404-406
    CrossrefPubMedGoogle Scholar
  • 4 Garrahy I, Forman D. Nitrofurantoin-induced radiation recall dermatitis. J Community Hosp Intern Med Perspect 2019; 9 (03) 279-281
    CrossrefPubMedGoogle Scholar
  • 5 Abadir R, Liebmann J. Radiation reaction recall following simvastatin therapy: a new observation. Clin Oncol (R Coll Radiol) 1995; 7 (05) 325-326
    CrossrefPubMedGoogle Scholar
  • 6 Extermann M, Vogt N, Forni M, Dayer P. Radiation recall in a patient with breast cancer treated for tuberculosis. Eur J Clin Pharmacol 1995; 48 (01) 77-78
    CrossrefPubMedGoogle Scholar
  • 7 Camidge R, Price A. Characterizing the phenomenon of radiation recall dermatitis. Radiother Oncol 2001; 59 (03) 237-245
    CrossrefPubMedGoogle Scholar
  • 8 Hellman S, Botnick LE. Stem cell depletion: an explanation of the late effects of cytotoxins. Int J Radiat Oncol Biol Phys 1977; 2 (1-2) 181-184
    CrossrefPubMedGoogle Scholar
  • 9 Seymour CB, Mothersill C, Alper T. High yields of lethal mutations in somatic mammalian cells that survive ionizing radiation. Int J Radiat Biol Relat Stud Phys Chem Med 1986; 50 (01) 167-179
    CrossrefPubMedGoogle Scholar
  • 10 Sibaud V. Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am J Clin Dermatol 2018; 19 (03) 345-361
    CrossrefPubMedGoogle Scholar
  • 11 Korman AM, Tyler KH, Kaffenberger BH. Radiation recall dermatitis associated with nivolumab for metastatic malignant melanoma. Int J Dermatol 2017; 56 (04) e75-e77
    CrossrefPubMedGoogle Scholar
  • 12 Dhanushkodi M, Iyer P, Ananthi B, Krishnamurthy A. Nivolumab-induced radiation recall dermatitis (RRD). Indian J Gynecol Oncol 2019; 17: 1-2
    Google Scholar
  • 13 Rouyer L, Bursztejn AC, Charbit L, Schmutz JL, Moawad S. Stevens-Johnson syndrome associated with radiation recall dermatitis in a patient treated with nivolumab. Eur J Dermatol 2018; 28 (03) 380-381
    CrossrefPubMedGoogle Scholar
  • 14 Ding X, Ji W, Li J, Zhang X, Wang L. Radiation recall pneumonitis induced by chemotherapy after thoracic radiotherapy for lung cancer. Radiat Oncol 2011; 6: 24
    CrossrefPubMedGoogle Scholar
  • 15 A First Report of Nivolumab induced Radiation Recall Pneumonitis | OncologyPRO. Available from: https:// oncologypro. Esmo. org/meeting-resources/esmo-asia-2016-congress/A-First-Report-of-Nivolumab-induced-Radiation-Recall-Pneumonitis. Accessed April 12, 2021
  • 16 Shibaki R, Akamatsu H, Fujimoto M, Koh Y, Yamamoto N. Nivolumab induced radiation recall pneumonitis after two years of radiotherapy. Ann Oncol 2017; 28 (06) 1404-1405
    CrossrefPubMedGoogle Scholar
  • 17 Thoré P, Godbert B, Petit I, Chaouat A. Radiation recall pneumonitis in a patient treated by nivolumab for non-small cell lung cancer, no relapse with rechallenge. J Med Oncol 2018; 3: 12
    Google Scholar
  • 18 Naiditch H, Brandsdorfer C, Possick JD. Imatinib-Induced Pneumonitis Associated with “Radiation-Recall” Pattern in a Patient with Chronic Myelogenous Leukemia and Prior Chemotherapy, Radiation Therapy, and Immunotherapy for Non-Small Cell Lung Cancer. In: American Thoracic Society International Conference Meetings Abstracts. American Thoracic Society; 2019. p. A1472–2
  • 19 Nakamura K, Okubo K, Takahashi T, Mitsumori K, Ishigaki T, Ohnishi H. Radiation recall pneumonitis induced by nivolumab in a patient with renal cell carcinoma. IJU Case Rep 2018; 2 (01) 30-33
    CrossrefPubMedGoogle Scholar
  • 20 Gupta K, Lee R, Sloan M. Diffuse lung disease session title: Drug-induced lung disease session type:. Affiliate Case report poster presented nivolumab-induced radiation recall pneumonitis. 2017; 152 (04) A463 Available at https://journal.chestnet.org/article/S0012-3692(17)32008-1/fulltext. Accessed April 21
    CrossrefGoogle Scholar
  • 21 van Seggelen WO, De Vos FY, Röckmann H, van Dijk MR, Verhoeff JJ. Occurrence of an abscopal radiation recall phenomenon in a glioblastoma patient treated with nivolumab and re-irradiation. Case Rep Oncol 2019; 12 (03) 896-900
    CrossrefPubMedGoogle Scholar
  • 22 Wang CM, Fleming KF, Hsu S. A case of vemurafenib-induced keratosis pilaris-like eruption. Dermatol Online J 2012; 18 (04) 7
    PubMedGoogle Scholar
  • 23 Anker CJ, Ribas A, Grossmann AH. et al. Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma. J Clin Oncol 2013; 31 (17) e283-e287
    CrossrefPubMedGoogle Scholar
  • 24 Boussemart L, Boivin C, Claveau J. et al. Vemurafenib and radiosensitization. JAMA Dermatol 2013; 149 (07) 855-857
    CrossrefPubMedGoogle Scholar
  • 25 Ducassou A, David I, Delannes M, Chevreau C, Sibaud V. Radiosensibilisation induite par le vémurafénib. Cancer Radiother 2013; 17 (04) 304-307
    CrossrefPubMedGoogle Scholar
  • 26 Conen K, Mosna-Firlejczyk K, Rochlitz C. et al. Vemurafenib-induced radiation recall dermatitis: case report and review of the literature. Dermatology 2015; 230 (01) 1-4
    CrossrefPubMedGoogle Scholar
  • 27 Forschner A, Zips D, Schraml C. et al. Radiation recall dermatitis and radiation pneumonitis during treatment with vemurafenib. Melanoma Res 2014; 24 (05) 512-516
    CrossrefPubMedGoogle Scholar
  • 28 Harding JJ, Barker CA, Carvajal RD, Wolchok JD, Chapman PB, Lacouture ME. Cutis verticis gyrata in association with vemurafenib and whole-brain radiotherapy. J Clin Oncol 2014; 32 (14) e54-e56
    CrossrefPubMedGoogle Scholar
  • 29 Braunstein I, Gangadhar TC, Elenitsas R, Chu EY. Vemurafenib-induced interface dermatitis manifesting as radiation-recall and a keratosis pilaris-like eruption. J Cutan Pathol 2014; 41 (06) 539-543
    CrossrefPubMedGoogle Scholar
  • 30 Houriet C, Klass ND, Beltraminelli H, Borradori L, Oberholzer PA. Localized epidermal cysts as a radiation recall phenomenon in a melanoma patient treated with radiotherapy and the BRAF inhibitor vemurafenib. Case Rep Dermatol 2014; 6 (03) 213-217
    CrossrefPubMedGoogle Scholar
  • 31 Haraldsdottir S, Bertino E, Haglund K, Kaffenberger B, Shah MH. Radiation recall dermatitis with concomitant dabrafenib and pazopanib therapy. JAMA Dermatol 2016; 152 (05) 587-589
    CrossrefPubMedGoogle Scholar
  • 32 Yilmaz M, Celik U, Hascicek S. Radiation recall dermatitis with dabrafenib and trametinib: a case report. World J Clin Cases 2020; 8 (03) 522-526
    CrossrefPubMedGoogle Scholar
  • 33 Ejlsmark MW, Kristiansen C, Eriksen JG, Hansen O, Bastholt L. Recall radiation myelitis after stereotactic radiation and dabrafenib in metastatic melanoma. Acta Oncol 2017; 56 (01) 109-110
    CrossrefPubMedGoogle Scholar
  • 34 Zheng YM, Chow JM, Chang CL, Chao LH, Whang-Peng J, Lai GM. Hematuria induced by combination regorafenib and hyperthermia - a radiation recall effect. Int J Hyperthermia 2019; 36 (01) 1186-1189
    CrossrefPubMedGoogle Scholar
  • 35 Tran WT, Ibáñez C, Pinto MP, Sanchez C, Czarnota GJ, Merino T. Eribulin-induced radiation recall dermatitis: a case report and brief review of the literature. Ecancermedicalscience 2020; 14: 1006
    PubMedGoogle Scholar
  • 36 Sanchis-Borja M, Parrot A, Sroussi D, Rivin Del Campo E, Fallet V, Cadranel J. Dramatic radiation recall pneumonitis induced by osimertinib after palliative thoracic radiotherapy for lung cancer. J Thorac Oncol 2019; 14 (10) e224-e226
    CrossrefPubMedGoogle Scholar
  • 37 Togashi Y, Masago K, Mishima M, Fukudo M, Inui K. A case of radiation recall pneumonitis induced by erlotinib, which can be related to high plasma concentration. J Thorac Oncol 2010; 5 (06) 924-925
    CrossrefPubMedGoogle Scholar
  • 38 Burris III HA, Hurtig J. Radiation recall with anticancer agents. Oncologist 2010; 15 (11) 1227-1237
    CrossrefPubMedGoogle Scholar
  • 39 Sasaki K, Iinuma S, Fujii M. et al. Radiation recall dermatitis induced by mogamulizumab. J Eur Acad Dermatol Venereol 2020; 34 (02) e107-e108
    CrossrefPubMedGoogle Scholar
  • 40 Masri SC, Misselt AJ, Dudek A, Konety SH. Radiation recall reaction causing cardiotoxicity. J Cardiovasc Magn Reson 2014; 16: 25
    CrossrefPubMedGoogle Scholar
  • 41 Moon D, Koo JS, Suh CO, Yoon CY, Bae J, Lee S. Radiation recall dermatitis induced by trastuzumab. Breast Cancer 2016; 23 (01) 159-163
    CrossrefPubMedGoogle Scholar
  • 42 Lee HE, Jeong NJ, Lee Y. et al. Radiation recall dermatitis and pneumonitis induced by trastuzumab (Herceptin®). Int J Dermatol 2014; 53 (03) e159-e160
    CrossrefPubMedGoogle Scholar
  • 43 Chung C, Dawson LA, Joshua AM, Brade AM. Radiation recall dermatitis triggered by multi-targeted tyrosine kinase inhibitors: sunitinib and sorafenib. Anticancer Drugs 2010; 21 (02) 206-209
    CrossrefPubMedGoogle Scholar
  • 44 Azad A, Maddison C, Stewart J. Radiation recall dermatitis induced by pazopanib. Onkologie 2013; 36 (11) 674-676
    CrossrefPubMedGoogle Scholar
  • 45 Levy A, Hollebecque A, Bourgier C. et al. Targeted therapy-induced radiation recall. Eur J Cancer 2013; 49 (07) 1662-1668
    CrossrefPubMedGoogle Scholar
  • 46 Clark D, Gauchan D, Ramaekers R, Norvell M, Copur MS. Radiation recall pneumonitis during systemic treatment with everolimus. Oncol Res 2014; 22 (5-6) 321-324
    CrossrefPubMedGoogle Scholar
  • 47 Visy A, Bachelot T, Racadot S. Radiation recall syndrome in a patient with breast cancer, after introduction of everolimus. Cancer Radiother 2019; 23 (05) 423-425
    CrossrefPubMedGoogle Scholar
  • 48 Ubukata M, Kamio T, Ohchi T, Noguchi E, Tsukada H, Kameoka S. Radiation recall dermatitis occurring 6 years and 4 months after breast-conserving surgery: a case report. Oncol Lett 2016; 11 (05) 3071-3074
    CrossrefPubMedGoogle Scholar
  • 49 Rafiroiu S, Vassil A, Valente SA. Quinolone-induced radiation recall dermatitis in breast cancer patient. Breast J 2020; 26 (07) 1407-1408
    CrossrefPubMedGoogle Scholar
  • 50 Grellety T, Houédé N, Hoepffner JL. et al. Hemorrhagic cystitis in patients treated with cabazitaxel: a radiation recall syndrome?. Ann Oncol 2014; 25 (06) 1248-1249
    CrossrefPubMedGoogle Scholar